Baillie Gifford Amends Moderna Stake, Signals Ownership Change

Ticker: MRNA · Form: SC 13G/A · Filed: 2024-01-29T00:00:00.000Z

Sentiment: neutral

Topics: institutional-ownership, amendment, biotechnology, investment-firm

TL;DR

**Baillie Gifford updated their Moderna holdings, watch for market reaction.**

AI Summary

Baillie Gifford & Co, a prominent investment management firm, filed an amended SC 13G/A on January 29, 2024, indicating a change in their beneficial ownership of Moderna, Inc. common stock as of December 29, 2023. This filing, Amendment No. 3, updates their previous disclosures regarding their stake in the biotechnology company. This matters to investors because large institutional holdings and changes can signal confidence or concern in the company's future prospects, potentially influencing stock price movements.

Why It Matters

Changes in significant institutional ownership can impact investor sentiment and stock valuation, as large firms often conduct extensive due diligence.

Risk Assessment

Risk Level: low — This filing is a routine update on institutional ownership and does not inherently signal a high-risk event for Moderna.

Analyst Insight

Investors should monitor subsequent filings from Baillie Gifford & Co for Moderna to understand the magnitude and direction of their ownership changes, as this could indicate a shift in their investment thesis.

Key Players & Entities

FAQ

What type of filing is this document?

This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, specifically Amendment No. 3 for Moderna, Inc.

Who is the filer of this SC 13G/A?

The filer of this SC 13G/A is BAILLIE GIFFORD & CO, an investment management firm.

What is the subject company of this filing?

The subject company of this filing is Moderna, Inc., identified by the CIK 0001682852.

What was the date of the event that required this filing?

The date of the event which required the filing of this statement was December 29, 2023.

Under which rule was this Schedule 13G filed?

This Schedule 13G was filed under Rule 13d-1(b), as indicated by the 'X' in the appropriate box.

From the Filing

0001088875-24-000040.txt : 20240129 0001088875-24-000040.hdr.sgml : 20240129 20240129104928 ACCESSION NUMBER: 0001088875-24-000040 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20240129 DATE AS OF CHANGE: 20240129 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Moderna, Inc. CENTRAL INDEX KEY: 0001682852 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 813467528 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-90749 FILM NUMBER: 24571178 BUSINESS ADDRESS: STREET 1: 200 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6177146500 MAIL ADDRESS: STREET 1: 200 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Moderna Therapeutics, Inc. DATE OF NAME CHANGE: 20160822 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BAILLIE GIFFORD & CO CENTRAL INDEX KEY: 0001088875 ORGANIZATION NAME: IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: CALTON SQUARE STREET 2: 1 GREENSIDE ROW CITY: EDINBURGH STATE: X0 ZIP: EH13AN BUSINESS PHONE: 00441312752000 MAIL ADDRESS: STREET 1: CALTON SQUARE STREET 2: 1 GREENSIDE ROW CITY: EDINBURGH STATE: X0 ZIP: EH13AN SC 13G/A 1 Moderna29122023.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 MODERNA, INC. (Amendment No.3) ----------------------------------------------------------------------- (Name of Issuer) Common Stock ----------------------------------------------------------------------- (Title of Class of Securities) 60770K107 ----------------------------------------------------------------------- (CUSIP Number) 29 December 2023 ----------------------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1745 (3-06) CUSIP No. 60770K107 _______________________________________________________________________ 1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only). Baillie Gifford & Co (Scottish partnership) _______________________________________________________________________ 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a).................................................................... (b).................................................................... _______________________________________________________________________ 3. SEC Use Only _______________________________________________________________________ 4. Citizenship or Place of Organization SCOTLAND UK _______________________________________________________________________ Number of 5. Sole Voting Power 37,518,682 Shares Bene ______________________________________________________ ficially by 6. Shared Voting Power 0 Owned by Each ______________________________________________________ Reporting 7. Sole Dispositive Power 45,654,527 Person With: ____

View on Read The Filing